| Literature DB >> 35034320 |
Giorgia Dalpiaz1, Lorenzo Gamberini2, Aldo Carnevale3, Savino Spadaro4, Carlo Alberto Mazzoli5, Sara Piciucchi6, Davide Allegri7, Chiara Capozzi8, Ersenad Neziri9, Maurizio Bartolucci10, Francesco Muratore11, Francesca Coppola12, Antonio Poerio13, Emanuela Giampalma14, Luca Baldini15, Tommaso Tonetti16, Iacopo Cappellini17, Davide Colombo18,19, Gianluca Zani20, Lorenzo Mellini21, Vanni Agnoletti22, Federica Damiani23, Giovanni Gordini5, Cristiana Laici24, Giuliano Gola25, Antonella Potalivo26, Jonathan Montomoli27, Vito Marco Ranieri16, Emanuele Russo22, Stefania Taddei28, Carlo Alberto Volta4, Gaetano Scaramuzzo4.
Abstract
PURPOSE: COVID-19-related acute respiratory distress syndrome (ARDS) is characterized by the presence of signs of microvascular involvement at the CT scan, such as the vascular tree in bud (TIB) and the vascular enlargement pattern (VEP). Recent evidence suggests that TIB could be associated with an increased duration of invasive mechanical ventilation (IMV) and intensive care unit (ICU) stay. The primary objective of this study was to evaluate whether microvascular involvement signs could have a prognostic significance concerning liberation from IMV.Entities:
Keywords: Acute respiratory distress syndrome; Mechanical ventilation; Novel coronavirus disease 2019; Pulmonary perfusion; Thoracic imaging
Mesh:
Year: 2022 PMID: 35034320 PMCID: PMC8761248 DOI: 10.1007/s11547-021-01444-7
Source DB: PubMed Journal: Radiol Med ISSN: 0033-8362 Impact factor: 6.313
Fig. 1CT scans showing vascular enlargement pattern (VEP) and vascular tree-in-bud (TIB) in two patients with COVID-19 pneumonia. Notes: A—Bilateral peripheral areas of ground-glass opacification and crazy paving in the upper lobes. Dilated segmental and subsegmental vessels (VEP—arrowheads) are visible inside these areas. B—Targeted image shows striking dilatation of peripheral subpleural vessel in upper left lobe with a branching aspect resembling a budding tree (arrow). Please note that vascular TIB is visible only within the area of ground-glass-opacity in this picture
Demographics, comorbidities, orotracheal intubation timing and ICU admission severity
| All ( | TIB ( | No TIB ( | VEP ( | No VEP ( | |||
|---|---|---|---|---|---|---|---|
| Age—yr (IQR) | 66 (57–74) | 67 (59–74) | 64 (57–74) | 0.404 | 68 (59–74) | 63 (56–70) | 0.115 |
| Sex—male—no (%) | 104 (74.8%) | 54 (72%) | 50 (78.1%) | 0.407 | 80 (74.1%) | 24 (77.4%) | 0.705 |
| BMI—median (IQR) | 28 (25–32) | 28 (25–31) | 29 (26–33) | 28 (25–31) | 28 (25–33) | 0.838 | |
| Hypertension—no (%) | 86 (61.9%) | 41 (54.7%) | 45 (70.3%) | 0.058 | 65 (60.2%) | 21 (67.7%) | 0.445 |
| Chronic ischemic heart disease—no (%) | 12 (8.6%) | 5 (6.7%) | 7 (10.9%) | 0.372 | 8 (7.4%) | 4 (12.9%) | |
| Chronic kidney disease (CKD) | 0.567* | 0.790* | |||||
| CKD—not in dialysis—no (%) | 7 (5.0%) | 2 (3.1%) | 5 (6.7%) | 6 (5.6%) | 1 (3.2%) | ||
| CKD—patients in dialysis—no (%) | 3 (2.2%) | 2 (2.7%) | 1 (1.6%) | 2 (1.9%) | 1 (3.2%) | ||
| COPD—no (%) | 8 (5.8%) | 6 (8.0%) | 2 (3.1%) | 0.267* | 6 (5.6%) | 2 (6.5%) | 0.852* |
| COPD—home oxygen therapy/CPAP—no (%) | 1 (0.7%) | 0 (0%) | 1 (1.6%) | 1 (0.9%) | 0 (0%) | ||
| Diabetes—no (%) | 36 (25.9%) | 18 (24%) | 18 (28.1%) | 0.580 | 30 (27.8%) | 6 (19.4%) | 0.345 |
| Time from hospital admission to ICU admission—d (IQR) | 1 (0–2) | 1 (1–3) | 1 (0–2) | 1 (0–3) | 1 (0–2) | 0.089 | |
| Time from hospital admission to intubation—d (IQR) | 1 (0–3) | 2 (1–3) | 1 (0–2) | 1 (0–3) | 1 (0–2) | 0.108 | |
| SAPS II score | 35 (29–43) | 35 (29–43) | 35 (30–46) | 0.488 | 35 (29–43) | 35 (29–46) | 0.757 |
| SOFA score at ICU admission | 5 (3–7) | 5 (3–7) | 5 (3–7) | 0.790 | 5 (3–7) | 5 (3–7) | 0.927 |
BMI body mass index, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ICU intensive care unit, SAPS simplified acute physiology score, SOFA sequential organ failure assessment, IQR interquartile range
Significant p values are reported in bold. *Refers to the p value of the Chi-square test for the whole contingency table for the variable taken into account
Ventilatory data, adjunctive therapies, ICU stay and outcomes
| All ( | TIB ( | No TIB ( | VEP ( | No VEP ( | |||
|---|---|---|---|---|---|---|---|
| Lowest PaO2/FiO2 ratio in supine position—(IQR) | 99 (72–132) | 102 (70–133) | 90 (75–129) | 0.546 | 100 (72–133) | 90 (65–115) | 0.360 |
| Lowest PaO2/FiO2 ratio in supine position—no (%) | 0.098* | 0.434* | |||||
| 200–300—no (%) | 6 (4.3%) | 4 (5.3%) | 2 (3.1%) | 5 (4.6%) | 1 (3.2%) | ||
| 100–200—no (%) | 62 (44.6%) | 39 (52.0%) | 23 (35.9%) | 51 (47.2%) | 11 (35.5%) | ||
| < 100—no (%) | 71 (51.1%) | 32 (42.7%) | 39 (60.9%) | 52 (48.1%) | 19 (61.3%) | ||
| Lowest static CRS—mL/cmH2O (IQR) | 40 (32–47) | 39 (30–47) | 40 (35–48) | 0.186 | 40 (32–47) | 40 (30–48) | 0.950 |
| CRS < 40 mL/cmH2O—no (%) | 65 (46.8%) | 38 (50.7%) | 27 (42.2%) | 0.318 | 49 (45.4%) | 16 (51.6%) | 0.539 |
| Neuromuscular blocking agents continuous infusion—no (%) | 124 (89.1%) | 67 (89.3%) | 57 (89.1%) | 0.959 | 97 (89.8%) | 27 (87.1%) | 0.667 |
| Any thromboprophylaxis—no (%) | 139 (100%) | 75 (100%) | 64 (100%) | 1.000 | 108 (100%) | 31 (100%) | 1.000 |
| Enoxaparin therapy—no (%) | 184 (89.2%) | 69 (92%) | 55 (85.9%) | 0.251 | 97 (89.8%) | 27 (87.1%) | 0.667 |
| Enoxaparin daily dose—mg (IQR) | 60 (40–80) | 60 (40–80) | 60 (40–80) | 0.393 | 60 (40–80) | 60 (40–80) | 0.782 |
| Intravenous corticosteroids—no (%) | 96 (69.1%) | 56 (74.7%) | 40 (62.5%) | 0.122 | 77 (71.3%) | 19 (61.3%) | 0.288 |
| Antiplatelet therapy—no (%) | 44 (31.7%) | 24 (32%) | 20 (31.3%) | 0.925 | 33 (30.6%) | 11 (35.5%) | 0.603 |
| Tracheotomy—no (%) | 89 (64.0%) | 44 (58.7%) | 45 (70.3%) | 0.154 | 72 (66.7%) | 17 (54.8%) | 0.226 |
| Prone positioning—no (%) | 83 (59.7%) | 43 (57.3%) | 40 (62.5%) | 0.536 | 65 (60.2%) | 18 (58.1%) | 0.832 |
| Cardiovascular complications—no (%) | 35 (25.2%) | 21 (28.0%) | 14 (21.9%) | 0.407 | 28 (25.9%) | 7 (22.6%) | 0.705 |
| Need for RRT—no (%) | 31 (22.3%) | 14 (18.7%) | 17 (26.6%) | 0.265 | 26 (24.1%) | 5 (16.1%) | 0.349 |
| Duration of MV—days (IQR) | 15 (9–24) | 15 (8–23) | 16 (8–24) | 0.297 | 15 (9–24) | 16 (9–23) | 0.652 |
| VFD-28 days—days (IQR) | 0 (0–14) | 0 (0–15) | 0 (0–12) | 0.979 | 0 (0–15) | 0 (0–12) | 0.980 |
| ICU length of stay—days (IQR) | 18 (12–32) | 19 (13–31) | 17 (9–33) | 0.558 | 19 (13–32) | 17 (9–33) | 0.652 |
| ICU mortality—no (%) | 57 (41.0%) | 32 (42.7%) | 25 (39.1%) | 0.667 | 46 (42.6%) | 11 (35.5%) | 0.478 |
C respiratory system compliance, IQR interquartile range
Significant p values are reported in bold. *Refers to the p value of the Chi-square test for the whole contingency table for the variable taken into account
Main radiologic findings
| Vascular signs and peripheral nodules—number of lobes involved | ||||||
|---|---|---|---|---|---|---|
| Present | 1 | 2 | 3 | 4 | 5 | |
| Vascular tree in bud—no (%) | 75 (54%) | 7 (9.3%) | 26 (34.7%) | 23 (30.7%) | 9 (12%) | 10 (13.3%) |
| Vascular enlargement pattern—no (%) | 108 (77.7%) | 3 (2.8%) | 24 (22.2%) | 26 (24.1%) | 17 (15.7%) | 38 (35.2%) |
| Peripheral nodules—no (%) | 24 (17.3%) | 2 (8.3%) | 10 (41.7%) | 9 (37.5%) | 3 (12.5%) | 0 (0%) |
Main distribution: A anterior, P posterior, D diffuse
Significant p values are reported in bold. *Refers to the p value of the Chi-square test for the whole contingency table for the variable taken into account
Fig. 2Spearman heatmap regarding the extension of the radiologic signs explored. Abbreviations: VEP—vascular enlargement pattern; TIB—tree in bud sign; GGO—ground glass opacities. Notes—the values reported in the cells refer to the rho coefficient for the bivariate correlation of the two variables; p < 0.05; *p < 0.01
Fig. 3Cumulative incidence functions of liberation from mechanical ventilation. Abbreviations: TIB—tree in bud; VEP—vascular enlargement pattern; MV—mechanical ventilation
Fig. 4Prevalence of extended radiologic signs in different contexts. Abbreviations: VEP—vascular enlargement pattern; TIB—tree in bud; PN—peripheral nodules; GGO—ground glass opacities; CP—crazy paving; Cons—consolidations. Notes: Graphs show the prevalence of VEP, TIB and PN involving 3 or more lobes and GGO, CP and Cons extended for over the 50% of pulmonary parenchyma. *p < 0.05 at Chi-square test